Gene fusions, in particular, represent a well-established paradigm of oncogenic drivers, and our analyses illuminate the molecular mechanism of the FGFR2::SHTN1 fusion, identifying it as a de novo oncogenic driver, particularly relevant to CCA. Here, FGFR2 is linked to cholangiocarcinoma.